StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Biogen
220.82
-0.06%
 

BIIB

 

Biogen

$ 220.82

 
-$0.13 | -0.06%
 
 
Open
$ 221.17
 
 
MKT CAP
$ 32.13B
 
High
$ 222.92
 
 
VOL
$ 771.52K
 
Low
$ 219.76
 
 
AVG VOL
$ 1.13M
 
 
 

BIIB Stock Analysis

  Login to display Biogen (BIIB) recommendation from the last 90 days from financial news and social media.
 
 

BIIB Total Score

 
 

Strengths

BIIB Rewards

 Earnings are forecast to grow

BIIB Rewards

 Outperform the market

BIIB Rewards

 Investors confidence is positive

 

Risk Analysis

BIIB Risk Analysis

 Trading above its fair value

 
 

Chart

 
 

248.3

233.87

257.45

258.99

 
 
1month
3month
6month
1year
 
Total Return
BIIB
vs.
S&P500
 

 
1-week Return
-1.39%
 
+1.04%
 
 
5-week Return
-9.80%
 
+4.91%
 
 
10-week Return
-12.27%
 
+7.60%
 
 
 

BIIB Risk Level

This Indicator assigning BIIB risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
BIIB Risk Level
LOW
HIGH

Risk Volatility

 

BIIB has Low Risk Level

Click here to check what is your level of risk

 

BIIB Analysts Opinion

BIIB overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.44
 

BIIB Earnings Sentiment

 Below analyst estimate

BIIB Earnings Sentiment

 Reported a weak earnings

BIIB Earnings Sentiment

 Revenue declined YoY

 
 

Rating

×
 

Rating

2.25
 
 

Momentum

×
 

Momentum

2.67
 

BIIB Momentum Analysis

 Price value has negative momentum

 

Activity

×
 

Activity

3.51
 

BIIB Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

3.33
 

BIIB Future Sentiment

 Earnings are forecast to grow

BIIB Future Sentiment

 Outperform the market

BIIB Future Sentiment

 Trading above its fair value

 
 

BIIB Analysts Opinion

BIIB Analysts opinion is negative but has improved from the past 3 months

 

BIIB Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
52%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
33%
67%
 
On Track
On Track
On Track
 

BIIB Street Opinion 

BIIB Street view is bullish and have positive views on the near-term outlook

 

BIIB Performance Sentiment

Sentiments overview associated with BIIB events and the stock performance.
 
52%
41%
Positive
Negative
33 out of 63
events present
26 out of 63
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

BIIB Earnings

The TTM reflects 12-month period, providing review of BIIB financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
9,993
10,173
10,982
-4.61%
 
 
Cost of Revenue
2,486
2,278
2,110
+8.54%
 
 
Gross Profit
7,507
7,895
8,872
-8.01%
 
 
Operating Exp
5,605
4,993
6,064
-3.86%
 
 
Operating Inc
1,902
2,902
2,808
-17.70%
 
 
Net Interest Inc
72
-157
-243
-
 
 
Interest Exp
230
247
254
-4.84%
 
 
Interest Inc
303
89
11
+424.84%
 
 
Other Income
-365
847
-820
-
 
 
EPS
10.14
20.96
10.44
-1.45%
 
 
Next Earnings Date: Apr 23, 2024
 
 
Similar to BIIB
Total Score
Close Price
%
Change

LLY

Eli Lilly and Company

3.70

792.28

+1.30%

 

LEGN

Legend Biotech Corporatio

N/A

64.51

-1.56%

 

ALKS

Alkermes plc

3.60

29.92

-1.06%

 
 
 
Highlights
Last Modify
Price
% Change

 
Approvals
1 Week Ago
223.32
+0.38%
 
Concerns
1 Week Ago
222.48
+0.62%
 
New Product
1 Week Ago
219.21
+0.06%
 
Concerns
2 Weeks Ago
223.35
+1.18%
 
Weak Earnings
2 Weeks Ago
220.74
-2.61%
 
 
 
joker
 
 
 
StocksRunner

Explore our BIIB Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our BIIB Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 

Most Trending

 

-7.16%

 
 

-2.54%

 
 

+13.55%

 
 
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

BIIB Rewards

 Earnings are forecast to grow

BIIB Rewards

 Outperform the market

BIIB Rewards

 Investors confidence is positive

 

Risk Analysis

 

BIIB Risk Analysis

 Trading above its fair value

 
 
 

BIIB Risk Level

 
 
 

The Indicator assigning BIIB risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
BIIB Risk Level
LOW
HIGH

Risk Volatility

 

BIIB has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

BIIB

 

Biogen

$ 220.82

 
-$0.13 | -0.06%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 221.17
 
 
MKT CAP
$ 32.13B
 
High
$ 222.92
 
 
VOL
$ 771.52K
 
Low
$ 219.76
 
 
AVG VOL
$ 1.13M
 
 
 

BIIB Analysis

  Sign in to view Biogen (BIIB) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

248.3

233.87

257.45

258.99

 
 
1month
3month
6month
1year
 
Total Return
BIIB
vs.
S&P500
 

 
1-week Return
-1.39%
 
+1.04%
 
 
5-week Return
-9.80%
 
+4.91%
 
 
10-week Return
-12.27%
 
+7.60%
 
 
 

BIIB Analysts Opinion

BIIB Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.44
 

BIIB Earnings Sentiment

 Below analyst estimate

BIIB Earnings Sentiment

 Reported a weak earnings

BIIB Earnings Sentiment

 Revenue declined YoY

 
 

Rating

×
 

Rating

2.25
 
 

Momentum

×
 

Momentum

2.67
 

BIIB Momentum Sentiment

 Price value has negative momentum

 

Activity

×
 

Activity

3.51
 

BIIB Activity Sentiment

 Investors confidence is positive

 

Future

×
 

Future

3.33
 

BIIB Future Sentiment

 Earnings are forecast to grow

BIIB Future Sentiment

 Outperform the market

BIIB Future Sentiment

 Trading above its fair value

 
 

BIIB Analysts Opinion

BIIB Analysts opinion is negative but has improved from the past 3 months

 

BIIB Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
52%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
33%
67%
 
On Track
On Track
On Track
 

BIIB Street Opinion 

BIIB Street view is bullish and have positive views on the near-term outlook

 
BIIB Performance Sentiment
Sentiments overview associated with BIIB events and the stock performance.
 
52%
41%
Positive
Negative
33 out of 63
events present
26 out of 63
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

BIIB Earnings

The TTM data reflects the most recent 12-month period, providing overview of BIIB financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
9,993
10,173
10,982
-4.61%
 
 
Cost of Revenue
2,486
2,278
2,110
+8.54%
 
 
Gross Profit
7,507
7,895
8,872
-8.01%
 
 
Operating Exp
5,605
4,993
6,064
-3.86%
 
 
Operating Inc
1,902
2,902
2,808
-17.70%
 
 
Net Interest Inc
72
-157
-243
-
 
 
Interest Exp
230
247
254
-4.84%
 
 
Interest Inc
303
89
11
+424.84%
 
 
Other Income
-365
847
-820
-
 
 
EPS
10.14
20.96
10.44
-1.45%
 
 
Next Earnings Date: Apr 23, 2024
 
Highlights
Last Modify
Price
% Change

 
Approvals
1 Week Ago
223.32
+0.38%
 
Concerns
1 Week Ago
222.48
+0.62%
 
New Product
1 Week Ago
219.21
+0.06%
 
Concerns
2 Weeks Ago
223.35
+1.18%
 
Weak Earnings
2 Weeks Ago
220.74
-2.61%
 
 
BIIB Latest News Feed

EU medicines regulator backs Biogens ALS drug. Europes medicines regulator said on Friday that it has recommended granting a marketing authorization for Biogens drug for a type of neurological disease known as amyotrophic lateral sclerosis.

Fri Feb 23, 2024

Activity

Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogens Leqembi According to Spherix Global Insights Neurologist Survey. EXTON PA Feb. 22 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modify

Thu Feb 22, 2024

Activity
Activity
Earnings

Healthy Returns: The launch of breakthrough Alzheimers drug Leqembi is off to a slow start. Good afternoon! The launch of the closely watched Alzheimer'.s drug Leqembi is off to a slow start. Still demand for the treatment from Biogen and its Japanese

Tue Feb 20, 2024

Activity

Commit To Buy Biogen At $220 Earn 9% Annualized Using Options. Investors considering a purchase of Biogen Inc (Symbol: BIIB) shares but cautious about paying the going market price of $223.43/share might benefit from considering selling puts

Thu Feb 15, 2024

Activity
Potential

Biotech Stock Roundup: BIIBs Q4 Results CBAY Up on GILDs Acquisition & Other Updates. It has been a busy week for the biotech sector with earnings results. Biogen BIIB reported disappointing re

Thu Feb 15, 2024

Activity
Activity

What Eli Lilly investors can learn from the slow launch of a competitors drug. The rollout of Alzheimers treatment Leqembi from Biogen is going slower than expected providing a read-through for Club stock Eli Lilly.

Thu Feb 15, 2024

Activity

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps Analyst Says. Tuesday) posted fourth-quarter 2023 sales of $2.39 billion missing the consensus of $2.46 billion down 6% Y/Y and. Adjusted EPS of $2.95 down 27% missing the consensus of $

Wed Feb 14, 2024

Activity
Earnings

Airbnb downgraded to Neutral despite Q4 beat: 4 big analyst cuts By. Investing.com — Here is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades at Airbnb Quidel Biogen and Palantir Technologies. InvestingPro users g

Wed Feb 14, 2024

Momentum
Rating

Wells Fargo downgrades Biogen to equal weight cites Skyclarys sales.

Wed Feb 14, 2024

Rating

DOJ issues subpoena for info on Biogens foreign operations.

Wed Feb 14, 2024

Activity

Biogens Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade).

Wed Feb 14, 2024

Activity
Activity
Earnings

Earnings call: Biogen projects growth amid new product launches and cost cuts.

Tue Feb 13, 2024

Activity
Activity

Biogen Becomes Oversold (BIIB). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical an

Tue Feb 13, 2024

Momentum

Biogen (BIIB) Q4 Earnings & Sales Miss Estimates Stock Falls. Biogen BIIB reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.95 which missed the Zacks Consensus Estimate of $3

Tue Feb 13, 2024

Earnings
Momentum

Biogen misses top-line and bottom-line estimates. initiates FY24 outlook.

Tue Feb 13, 2024

Earnings

Biogen slips as outlook disappoints amid flat Leqembi sales.

Tue Feb 13, 2024

Activity
Activity
Momentum

Biogen Inc. Q4 Profit Decreases misses estimates. (RTTNews) - Biogen Inc. (BIIB) reported earnings for fourth quarter that decreased from last year and missed the Street estimates.

Tue Feb 13, 2024

Earnings

Biogen expects to return to profit growth this year. Biogen forecast a return to annual profit growth following cost cuts and a pick up in sales of its newer drugs but the companys shares fell 5% in premarket trading on Tuesday after missing Wal

Tue Feb 13, 2024

Activity
Earnings

Biogen revenue and profit shrink on Aduhelm costs slumping sales of multiple sclerosis therapies. The results come amid the rollout of Biogen and Eisais Leqembi the first drug found to slow the progression of Alzheimers to win FDA approval.

Tue Feb 13, 2024

Activity
Momentum

Biogen Shares Fall After Results Miss Expectations.

Tue Feb 13, 2024

Earnings
Momentum

Biogens Skyclarys Approved In Europe For Friedreichs Ataxia Treatment. (RTTNews) - Biogen Inc. (BIIB) said that the European Commission has authorized Skyclarys (omaveloxolone) for the treatment of Friedreichs ataxia in adults and adolescents ag

Tue Feb 13, 2024

Activity

Biogens rare genetic disorder drug gets approval in EU. Biogen said on Monday the European Commission has approved its drug for treating a rare genetic disorder that causes progressive damage to the nervous system in adults and adolescents ag

Mon Feb 12, 2024

Activity

AptarGroup (ATR) Inks Deal to Create Digital Health Solutions. AptarGroup Inc.&rsquo.s ATR Aptar Digital Health announced it signed an enterprise agreement with Biogen Inc. BIIB to operate and

Mon Feb 12, 2024

Activity

3 Millionaire-Maker Stocks to Buy While the Gettin Is Good. For patient long-term investors these three names can become millionaire-makers In order to turn $50000 into $1 million by investing you have to find stocks that the Street is underestimating. Of

Mon Feb 12, 2024

Potential

aptar inks enterprise agreement with biogen. (rttnews) - aptargroup inc. (atr) announced on friday that its subsidiary aptar digital health has signed an enterprise agreement with biogen inc. (biib).

Fri Feb 9, 2024

Activity

biogen inc. (biib) stock sinks as market gains: heres why. in the latest market close biogen inc. (biib) reached $240.30 with a -0.1% movement compared to the previous day. this change lagged t

Thu Feb 8, 2024

Momentum
Momentum

thursday links: stand alone statements. january 2024 how major asset classes performed in january 2024. (capitalspectator.com) the s&.p 500 was in positive territory for the month in contrast with small and mid caps. (on.spdji.com) strategy overconfide

Thu Feb 1, 2024

Activity

biogen drops aduhelm efforts after controversial speedy approval. more than two years after aduhelm'.s controversial and ill-fated fda accelerated approval biogen is discontinuing the alzheimer'.s disease therapy after walking a rocky path. wednesda

Thu Feb 1, 2024

Activity

controversial alzheimers drug exits the stage. aduhelm — the pricey alzheimer'.s drug that sparked congressional scrutiny of the food and drug administration'.s process for fast-tracking approvals as well as fears of medicare insolvency — is coming

Thu Feb 1, 2024

Potential

ticker: biogen to stop selling alzheimers drug. wynnbet betr look to exit mass. mobile sports betting. biogen will stop selling its alzheimers treatment aduhelm a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. th

Wed Jan 31, 2024

Activity
Momentum

 
 
 
 
 

Score Tracker

 
 
 
Based on 63 events in the last 90 days from financial news and social media. Last updated Mar 4, 2024 20:32 Wall St. time
 
 

BIIB Total Score

 
 
 
 
 
 
 
StocksRunner

Discover BIIB Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of BIIB. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our BIIB Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BIIB Stock trends

BIIB Stock performance

BIIB Stock analysis

BIIB investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker